Advertisement
Australia markets closed
  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     
  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     
  • AUD/USD

    0.6533
    +0.0010 (+0.16%)
     
  • OIL

    83.90
    +0.33 (+0.39%)
     
  • GOLD

    2,360.70
    +18.20 (+0.78%)
     
  • Bitcoin AUD

    98,564.23
    +1,394.23 (+1.43%)
     
  • CMC Crypto 200

    1,392.13
    -4.40 (-0.32%)
     
  • AUD/EUR

    0.6087
    +0.0014 (+0.23%)
     
  • AUD/NZD

    1.0977
    +0.0020 (+0.18%)
     
  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     
  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     
  • FTSE

    8,111.57
    +32.71 (+0.40%)
     
  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     
  • DAX

    18,051.36
    +134.08 (+0.75%)
     
  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

Why AbbVie Just Made a $1.8 Billion Gene Therapy Deal

AbbVie (NYSE: ABBV) recently announced a collaboration with Regenxbio (NASDAQ: RGNX) to develop a gene therapy targeting wet age-related macular degeneration. The deal could be worth up to nearly $1.8 billion including milestone payments. In this Motley Fool Live video recorded on Sept. 15, Motley Fool contributors Keith Speights and Brian Orelli discuss why AbbVie is teaming up with Regenxbio.